Liquidia Corp - Earnings Call - Q3 2025

Executive Summary

• Liquidia delivered a decisive beat in its first full quarter post‑launch: revenue of $54.3M vs Street ~$19.5M*, EBITDA turned positive, and GAAP net loss narrowed to $(3.5)M; operating income was $1.8M as YUTREPIA net product sales reached $51.7M. EPS of $(0.04) beat consensus of ~$(0.40)* materially.
• YUTREPIA launch metrics show strong adoption: >2,000 unique prescriptions, >1,500 patient starts, and >600 prescribers as of Oct 30, with ~85% referral‑to‑start conversion; voucher utilization ticked above 50% for new patients.
• Commercial enablers strengthened: contracts with the three largest commercial payers, removal of new‑to‑market blocks underway/complete, and specialty pharmacy inventory normalized at ~3–4 weeks.
• Momentum and cash: September was the first month of positive net cash flow (~$5M) with continued gains in October; cash and equivalents were $157.5M at Q3 end.
• Key watch item: ongoing litigation with United Therapeutics carries a wide range of potential remedies (from royalty to market withdrawal), with timing of a decision uncertain (window could extend into Q1).

What Went Well and What Went Wrong

What Went Well

• Commercial traction exceeded expectations: “Utrepia continued to exceed expectations on every front” with >2,000 Rx, >1,500 patient starts, and >600 prescribers; conversion from referral to start ~85%.
• Early profitability milestones: first full quarter operating income of $1.7M and positive adjusted EBITDA of $10.1M; September was first month of positive net cash flow (~$5M) with momentum into October.
• Access and pull‑through improving: contracts with three major commercial payers and new‑to‑market blocks removed or being removed, supporting high pull‑through (“~85% of referrals converted into a script”).

What Went Wrong

• GAAP still at a loss due to SG&A and interest: Q3 GAAP net loss of $(3.5)M; SG&A nearly doubled YoY to $40.1M (commercial build‑out, legal), and total other expense rose to $(5.3)M on higher HCR borrowings.
• Service revenue pressure: Sandoz promotion revenue fell to $2.7M vs $4.4M YoY, reflecting lower volumes; similar trend noted in Q2 (managed care adjustments).
• Ongoing litigation overhang: management underscored a wide range of potential outcomes (including injunctive relief or royalty); timing uncertain, likely within a broad window into early 2026.

Transcript

Operator (participant)

Good morning and welcome to the Liquidia Corporation Third Quarter 2025 Financial Results and Corporate Update Conference call. My name is Carmen, and I will be your operator today. All participants are currently in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. Instructions for joining the queue will be provided at that time. Please note that today's call is being recorded. I will turn the call over to Jason Adair, Chief Business Officer.

Jason Adair (Chief Business Officer)

Thank you, Carmen, and good morning, everyone. It's my pleasure to welcome you to Liquidia's Third Quarter 2025 Financial Results and Corporate Update Conference Call. Joining me today are Dr. Roger Jeffs, Chief Executive Officer; Michael Kaseta, Chief Operating Officer and Chief Financial Officer; Dr. Rajeev Saggar, Chief Medical Officer; Scott Moomaw, Chief Commercial Officer; and Rusty Schundler, General Counsel. Before we begin, please note that today's discussion will include forward-looking statements, including statements regarding future results, product performance, and ongoing clinical or commercial activities. These statements are subject to risks and uncertainties that may cause actual results to differ materially. For further information, please refer to our filings with the SEC available on our website. Please note that our earnings release, our commentary, and our slide deck accompanying this call include non-GAAP financial measures.

Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures can be found in our earnings release and the slide deck accompanying this call. With that, I'll turn the call over to Roger Jeffs, our Chief Executive Officer. Roger.

Roger Jeffs (CEO)

Thanks, Jason, and good morning, everyone. This morning, I want to begin by expressing just how proud we are in what Liquidia has accomplished in a remarkably short period of time. Over the last 5 months, we've not only brought a new and meaningful medicine into the treatment of patients living with PAH and PH-ILD, but we've also begun to influence the way physicians consider how to best introduce a prostacyclin into various treatment regimens. Every day, we hear stories from physicians and patients who are thankful to now have an inhaled prostacyclin that fits their lives, one that's simple and well-tolerated. For too long, patients faced limited and difficult choices. YUTREPIA is offering them an attractive alternative. The results speak for themselves. In the third quarter, YUTREPIA continued to exceed expectations on every front.

As of October 30th, we've received more than 2,000 unique prescriptions, initiated therapy for over 1,500 patients, and have over 600 healthcare practitioners who have prescribed YUTREPIA across the U.S. In fact, October is our highest month yet for referrals. Through the third quarter, the vast majority of prescriptions are converting to active patient starts, with a referral-to-start ratio hovering around 85%, an incredible figure for a new-to-market therapy and a true testament to the strength of our commercial and market access infrastructure. We've seen broad application of YUTREPIA, and I'd like to share some details on usage patterns. PAH has accounted for a majority of total prescriptions, with the use in PH-ILD growing steadily. Approximately three out of four patients starting YUTREPIA are new to treprostinil, while about one in four are transitioning from other prostacyclin therapies, typically inhaled.

Switches from Tyvaso products are similar for both indications at roughly 25% of prescriptions. Notably, around 10% of PAH prescriptions represent switches from oral therapies, a meaningful indicator that physicians may be starting to view YUTREPIA as a viable option to improve exposure and tolerability for patients who are struggling with systemic side effects from their oral prostacyclin therapy. This balance of naive and transition patients demonstrates the flexibility of YUTREPIA across real-world settings in specialized centers and community practices. The feedback we're hearing has been consistent. Many physicians find YUTREPIA easy to initiate, faster to titrate, and better tolerated than other available options, while patients appreciate the convenience and confidence that come with a palm-size, low-effort device. YUTREPIA isn't just gaining traction; it's redefining expectations for inhaled delivery of treprostinil, where exposure drives efficacy, tolerability drives durability, and convenience drives compliance.

We intend to translate this early commercial success into long-term sustainable growth. As Michael explained, Liquidia achieved profitability in its first full quarter following launch, and we are well-positioned to reinvest in innovation without compromising our financial discipline. Our clinical strategy in the near term intends to broaden YUTREPIA's clinical utility. We are actively planning niched, open-label studies to further strengthen the product profile. For example, to help inform what we are already seeing in the field, we will initiate a study in PAH patients transitioning from oral prostacyclin to YUTREPIA. Considering the recent interest in ILD indications, we are evaluating the feasibility of proof-of-concept studies with YUTREPIA in IPF and PPF.

We will also explore how YUTREPIA may be used to treat other diseases where patients have unmet needs, and smart trial design can expand the value of well-tolerated inhaled treprostinil, with opportunities in PH-COPD and Raynaud's phenomenon as examples. As you heard during our R&D day, we will further optimize inhaled treprostinil with L606, our sustained-release formulation that is rapidly delivered twice daily with a palm-sized nebulizer. We believe that the week 48 data from our U.S. clinical study already demonstrates that L606 may be the most tolerable inhaled treprostinil developed, with clear signals of efficacy in PAH and PH-ILD patients, whether transitioning from Tyvaso or naive to prostacyclin. Our global pivotal study, called RESPIRE, will initiate later this year and planned enrollment to start in the first half of 2026.

Now, let me hand the call over to Mike to explain how we can maintain our trajectory for increasing the overall value of the company. Mike.

Michael Kaseta (COO and CFO)

Thank you, Roger, and good morning, everyone. The third quarter of 2025 was truly a breakthrough quarter for Liquidia, both operationally and financially. During the quarter, our first full quarter of launch, we delivered $51.7 million in net product sales of YUTREPIA. We accomplished this while total R&D and SG&A expenses remained relatively flat compared to second quarter 2025. For the quarter, the company recorded a net loss of $3.6 million. However, when viewed on a non-GAAP basis, we generated positive adjusted EBITDA of $10.1 million in the first full quarter of YUTREPIA sales, much sooner than our previous guidance of profitability within three to four quarters post-launch. Cash on hand at the end of the quarter totaled $157.5 million.

Of particular note, I'm especially pleased to say that September marked our first month of positive net cash flow, a major operational milestone that highlights both our rapid success and disciplined approach to cash management. During September, we added $5 million in net cash, and we've continued to build on that momentum with additional gains in October. Looking ahead, we expect this positive trend to extend into 2026 as we stay focused on driving profitability while reinvesting in R&D to support sustained long-term growth. Roger, back over to you.

Roger Jeffs (CEO)

Thanks, Mike. As we close out this quarter, I want to emphasize the three key foundational elements that are truly defining the success of Liquidia both now and into the future. One, we have a product in YUTREPIA that is rapidly influencing the standard of care. Two, we have quickly established a strong, profitable operating foundation. Three, we have a disciplined growth strategy focused on expanding indications and value for YUTREPIA while also advancing our next-generation product, L606. These pillars, innovation, execution, and reinvestment, are what will guide us as we end this year and enter 2026. Above all, I want to thank our team, our clinical partners, and the patients who trust us. They are the reason we continue to deliver with both passion and precision. With that, operator, please open the line for questions.

Operator (participant)

Thank you so much. As a reminder to ask a question, simply press star one one on your telephone and wait for your name to be announced. To remove yourself, press star one one again. Please stand by for our first question, please. Comes from the line of Amy Li with Jefferies. Please proceed.

Amy Li (Analyst)

Hey, thanks so much for taking our question and congrats on the incredible launch. Based on our back-of-the-envelope math, we're getting to around 1,000 patient adds this quarter, which is doubling what Tyvaso, Tyvaso DPI reported in their 500 quarter-over-quarter adds earlier in their launch. Can you give us a sense of what's driving this uptake and, in particular, the breakdown between PAH and PH-ILD? And then finally, how are you thinking about the trajectory of patient adds going forward?

Roger Jeffs (CEO)

Hi, Amy. Thanks for the question. Again, we won't really comment more specifically than what we already have in the earnings release on numbers, but I think what you're seeing is very strong demand in the first 5 months of launch, completely driven by the product profile of YUTREPIA, which is unique and certainly is well on its way to becoming the established prostacyclin of first choice, not only in the inhaled market, but as we alluded to, we're starting to see oral transition so we can offset some of the GI toxicities with the oral. What we're also seeing somewhat is in the patients that have added sotatercept and maybe "normalizing" as they de-escalate the parenteral therapy, they're replacing that with YUTREPIA so that they can keep the prostacyclin pathway addressed. There's a lot of, I would say, growing opportunity.

I think if you look at the first 5 months, we've obviously seen very strong demand based on the profile. October, as we said, has had a slight uptick versus the previous month, so we're still on an attractive runway. While we can't predict growth in the future, and certainly there will be some seasonality and I think some ordering choppiness at the early phase of launch, I think we'll continue to execute well, and we feel very good about our future prospects. Maybe Scott, if I could ask you to maybe highlight some of the things that you think as Chief Commercial Officer that have highlighted the quarter and address more specifically some of Amy's questions.

Scott Moomaw (Chief Commercial Officer)

Yeah, thanks. Good morning. I think that the things that we're focused on right now is one is we're continuing to increase breadth. We're still in launch phase. We're still out there getting awareness and trial. We feel like we have an amazing opportunity still to drive to new prescribers. At the same time, we're still looking at depth from the current prescribers. Each day, we have new prescribers that are over the five prescription mark, which shows, I think, an amazing amount of investment at those centers. We think there's a lot of opportunity left out there. I think, Amy, I think you asked about the PAH, PH-ILD split. One thing we will comment on there is we have seen that PAH is a majority of the prescriptions. However, PH-ILD is definitely growing steadily, which is kind of what you would expect.

I think PAH was probably a little bit more, if you will, the lower-hanging fruit, and PH-ILD is a growing market, as we all know, and the sky's the limit as far as that goes.

Amy Li (Analyst)

Thank you so much.

Operator (participant)

Thank you. One moment for our next question. That comes from Cory Jubinville with LifeSci Capital. Please proceed.

Cory Jubinville (Analyst)

Hey, good morning. Thanks for taking our question and congrats on this really exciting update. I guess, can you just speak to what percentage of revenues might be associated with contracted versus non-contracted reimbursement? I mean, at this point, are you on the formularies for the three major PBMs? I'd say the script volume and the prescriber cost is strong, of course, but I think the revenues being recognized to this magnitude this early definitely far exceeds expectations. Just trying to get a sense of what some of those key drivers were in order for you to convert volume to revenues this quickly. Thank you.

Roger Jeffs (CEO)

Yeah, good morning, Cory. Great question. We have certainly spent a lot of effort and energy on the market access initiatives. Mike, if I could ask you to comment on the specific question.

Michael Kaseta (COO and CFO)

Yeah, thanks, Roger, and thanks for your question, Cory. Specifically around payers, I think it is also a testament of where we are right now on our pull-through. As we said, we've pulled through approximately 85% of referrals have converted into a script. That's a testament to what we had talked about at launch of building these patient support services that will enable that smooth transition, and we're very proud of what we've done there. Now, as it relates to payers, as we've previously stated, we've signed contracts with the three major commercial payers. The new market blocks that we referred to previously have or will be removed here in the coming weeks. As it relates to what is contracted and what is not contracted, to date, as you know, there is no contracting in Medicare Part D, so we are on even footing there.

In commercial, we have started to have contracted and started to receive, start to pay rebates there. As we move forward, as we've always said, we wanted to make sure that patients had an ability to make a choice, and we feel that we have achieved that now and look forward to the future where if a patient wants to choose YUTREPIA, that they will not be blocked by virtue of a contracting issue.

Cory Jubinville (Analyst)

Very helpful. Thanks. Congrats again.

Operator (participant)

Thank you. Our next question is from Julian Harrison with BTIG. Please proceed.

Julian Harrison (Analyst)

Hi, good morning. Congrats on the quarter, and thank you for taking the questions. Of the 1,500 patients on YUTREPIA at the end of last week, are you able to say how many were in the 28-day voucher period at that time? Also, average time from prescription written to YUTREPIA being shipped to a patient, what is that currently looking like?

Roger Jeffs (CEO)

Yeah, hi, Julian. It was good to see you last week at the R&D day. Mike, if you could answer the question, please.

Michael Kaseta (COO and CFO)

Yeah, so thanks, Julian. In terms of average time from time a prescription is written to when it's filled, what we're seeing is it's usually within a few weeks, which is pretty customary for SPs. We have a cross-functional focus on pulling through every prescription from market access to field reimbursement managers with the SPs, which is in constant coordination with the HCP office. Now, as it relates to our voucher program, again, the voucher program that we offer patients to give them an opportunity to try YUTREPIA with a free 28-day first shipment, that has ticked up a bit. We are now a bit over 50% of our new patients are using the voucher program, which was slightly higher from where we were when we had our call in August. We feel it's a great opportunity for patients and doctors to trial YUTREPIA.

If it works for them, then they can continue on their journey. For now, the expectation and where we are is slightly over 50% are using the voucher program.

Julian Harrison (Analyst)

Excellent. Thank you, Mike. And just to clarify, 50% have utilized the voucher program or were using it as it ended last week?

Michael Kaseta (COO and CFO)

From launch to date, we were slightly over 50%, yes.

Julian Harrison (Analyst)

Thank you.

Operator (participant)

Thank you. One moment for our next question, please. It is from Ryan Deschner with Raymond James. Please proceed.

Ryan Deschner (Analyst)

Thanks, and congrats on the quarter. In second quarter, you reported an elevated level of channel loading, and just wanted to ask how this metric is trending in third quarter and into October. I may have missed it at the beginning. If you could comment again on naïve versus treprostinil-experienced patients. Thanks.

Roger Jeffs (CEO)

Yeah. Hi, Ryan. Good morning. I'm not sure specifically what you're asking about channel loading because I don't think we commented on that specifically in the prior quarter. In terms of naive versus transition patients, it's been about 75% have been new to prostacyclin therapies and 25% have been transitions, typically from inhaled. Although you can see in PAH where the orals are only approved and not in PH-ILD, we are seeing 10% transitions there. I think one thing that question is related is kind of are we growing the market versus just taking share? I think the correct answer is yes, we are. I think the market's growing now with a second company in there driving awareness. When you look at things sequentially, I'd say second quarter to third quarter, I think we're capturing the lion's share of this new opportunity.

For example, I think it was reported last week that Tyvaso increased in aggregate across the nebulized and Tyvaso DPI franchise, $14.8 million, whereas we're now from Q2 to Q3, we've grown by $45.2 million. That represents the revenue growth. Of that revenue growth, we've captured 75% of that, which we're very, very pleased about. A lot of opportunity here to grow the market. I think with the product profile, the commercial acumen, and the ability that we've had to drive immediate awareness around the value of YUTREPIA, you're seeing that the uptake is leaning in a one-sided manner towards YUTREPIA. I don't think we've commented on channel loading, but we can get back to you on that later if that's helpful.

Ryan Deschner (Analyst)

Got it. Thanks, Roger.

Operator (participant)

Thank you. Our next question is from Serge Belanger with Needham. Please proceed.

Serge Belanger (Analyst)

Hi, good morning, and congrats on the first quarter of launch. First question regarding care coverage. Can you kind of give us an update now on when you expect to be at a steady state of coverage? I believe your competitor had entered some contracts with some commercial plans. Just curious if that has led to some headwinds for coverage of YUTREPIA. Lastly, maybe just expand a little bit on your plans to explore YUTREPIA usage in IPF and PPF. Thanks.

Roger Jeffs (CEO)

Great. Mike handles payer access questions. If you'll handle the first question, and then Rajeev, if you wouldn't mind speaking to our explorations in IPF.

Michael Kaseta (COO and CFO)

Yes, Serge, great to hear from you. Thanks for the question. As it relates to payers, and you referenced United's comments that they had contracted. In the commercial space, which we've spoken previously about, that they contracted at a parity level. As I said earlier, we have signed commercial contracts with the three largest payers. New-to-market blocks have been removed or are in the process of being removed. As a result of that, we feel that we will be on equal footing with United as it relates to that. We feel very confident in our strategy, very confident in where we sit right now that will enable us to have future growth. One other point I just want to go back to is around the channel loading. Obviously, at launch, the channel loading, but prior to launch, SPs are making an assumption of what's needed.

What I would say is we have settled into where I believe is a normal level of inventory. If you want to say that SPs hold somewhere between three and four weeks of inventory, we have leveled off there. We have great relationships with the SPs to understand where ordering patterns are. We are very confident in, as we move forward, that that can be managed appropriately and feel that we are in line with what our expectations would be.

Roger Jeffs (CEO)

Great. Rajeev, if you'll speak to the clinical question.

Rajeev Saggar (Chief Medical Officer)

Yeah, thanks, Serge, for the question. I mean, I think there's a few lessons coming out of TETON 2 that highlight that. Inhaled treprostinil appears to slow the progression of forced vital capacity in patients specifically with IPF over a course of 52 weeks. I think the other thing that continues to be something that we as a company and with YUTREPIA are in full agreement is that dose matters. Once again, lo and behold, it strongly suggests in TETON 2 that if you can dose the patient as high as up to 12 breaths, these patients did much better than if the patient cannot get to at least a minimum of 9 breaths.

I think obviously our sense study strongly suggests that if we can even dose even higher to that, we actually, and earlier, we potentially can even improve overall patients in regards to exercise capacity, at least in PH-ILD. If you take the entirety of that situation, the PPF study has not read out yet, but this suggests that I think YUTREPIA has a very strong product profile that may have some significant advantages over Tyvaso in regards to potentially ease of use, dosing and titratability, and overall tolerability effect. I think as an organization, we're extremely interested in evaluating and considering this pathway as we move forward.

Roger Jeffs (CEO)

Yeah, thank you, Rajeev. As you stated, this is a real period of renaissance for inhaled treprostinil. I think the value that YUTREPIA brings and the market opportunity expansion is immense. With L606, we have a next-generation opportunity to really complete this paradigm shift over time.

Serge Belanger (Analyst)

Thank you.

Operator (participant)

Thank you. Our next question is from Andrew Fein with H.C. Wainwright & Co. Please proceed.

Andrew Fein (Analyst)

Hi, good morning, everyone. Congratulations. I guess, look, strong sales are always a great thing, and patient demand being high is always a great thing. Maybe you can speak to the heightened importance of it in the context of the ongoing litigation with United Therapeutics and the read-through of the strength of sales and strength of patient demand and clear perceived differentiation in any way between the products as we continue the litigation outcome.

Roger Jeffs (CEO)

Yeah, Andrew, it was a little bit difficult to hear the question specifically. I could hear that you were asking about the litigation and how that's affecting demand.

Andrew Fein (Analyst)

Yeah, the read-through to the robust commercial environment to the litigation.

Roger Jeffs (CEO)

Yeah, I think the simple answer to that is physicians and prescribers in general aren't that aware of the litigation. Their only concern is patient benefit. I think our goal has been to expose the centers to the value of YUTREPIA, get them to try it, particularly within the centers of excellence, and then drive further demand. I think that's their concern. What happens in a court of law is outside of their jurisdiction, so they don't technically pay any attention to it. To me, there's not a lot of read-through in terms of how that litigation has impacted the uptake. As you can see, the uptake has been robust. I don't know that.

Andrew Fein (Analyst)

How does it impact the landscape of thought processes Judge Young might go through in deciding his outcome of the litigation? The more the commercial impact that Judge Young sees.

Roger Jeffs (CEO)

Yeah, yeah, understood. Okay. Maybe Rusty, if you can comment on the sort of balance of equities and harm.

Rusty Schundler (General Counsel)

Yeah, so we don't. Again, it's hard to predict how a judge is going to consider. Or even whether he'd consider commercial results, if that's the question. I think the judge is going to be thorough in thinking through the evidence that was presented to him and evaluate and come up with a decision. Again, I don't think he's going to be taking into account what's happening in the marketplace, sort of post-trial, and coming up with his decision. That was the question.

Andrew Fein (Analyst)

That's helpful. Thank you.

Roger Jeffs (CEO)

Yeah, maybe just take this opportunity to just remind listeners today that the value of the opportunity in PAH alone, I think the oral therapies are doing around $2 billion currently. The inhaled, if you just split the Tyvaso revenue in half, you'd say it's close to $1 billion. And then orals are around, I mean, parentals are around $500 million. You can easily get to a $3.5 billion current-day revenue opportunity in PAH alone. As you can see, we think the attractiveness that YUTREPIA offers can lead to a leading position across all three of those segments, the oral, inhaled, and the steal of parental share. Again, I know there's some concern around what may or may not happen with 327, but I think even if you took it in isolation, this is a tremendous opportunity that we have in front of us.

Operator (participant)

Our question is from Ben Burnett with Wells Fargo. Please proceed.

Ben Burnett (Analyst)

Hey, thank you very much, and congrats on the quarter. I just want to follow up on that last question. I guess I think we were maybe anticipating an update from a legal update. Just curious if the timing, from what you're hearing on your end, is any changed. I guess maybe could you also just remind us as to what exactly we'll get? Should we get an understanding of any sort of ramifications, or is this just purely a decision around this patent that you mentioned? Thank you.

Roger Jeffs (CEO)

Yeah, thanks, Ben. Rusty?

Rusty Schundler (General Counsel)

Yeah, thanks, Ben. So I mean, as far as timing goes, let me address that first. Obviously, there's no deadline for judges to rule in cases. I think the judge, the caseload in Delaware is pretty high. I think the judge is going to be throwing his opinion, but we don't have visibility as to when that decision will come. I think if you look at the time it took him to render a decision in the first Hatch-Waxman case a few years ago, I'd say we're in the window when we'd expect an opinion. The window is a pretty wide window. I think any time between now and sometime in the first quarter even would not be unexpected.

As far as sort of what we would hear from the judge, I think, again, if you look at the last case as a proxy, I think what we'd expect here first is just a decision, essentially as to who won. Typically there's then a second step where the parties then put in front of the judge what they propose the consequence of that decision is, one way or the other. If there's a disagreement between the parties, there's potentially additional hearings or whatever the judge wants to do to work through that. At least as far as the initial step is, our expectation is just going to be an opinion as to who won and who lost.

Ben Burnett (Analyst)

Okay. Thank you.

Operator (participant)

Thank you. Our last question comes from the line of Jason Gerbery with Bank of America. Please proceed.

Jason Gerberry (Analyst)

Hey, good morning, guys. Thanks for taking my question. One litigation follow-up. Do you have a sense whether a royalty is a possible remedy depending on outcomes of the case as opposed to I think there's a lot of, I guess, thought that perhaps an outcome if there was patent infringement would just be removing ILD from the label. I just kind of would love to get your perspective on that. As we look to 2026, why wouldn't it be reasonable to assume there's at least 2,000 patients on paid drug next year? Just given the trends and what we're seeing, just love to get your perspective on that. Thanks.

Roger Jeffs (CEO)

Yeah, Rusty, if you'll answer the litigation question, please.

Rusty Schundler (General Counsel)

Yeah, Jason, thanks for the question. I think there's a wide range of possible remedies here. It just is very dependent on exactly what the judge rules. I think the sides have put in arguments. The consequence ranges from YUTREPIA being removed from the market to a royalty. And those are all in sort of the downside scenarios. Again, it's just highly dependent on exactly how the judge rules. I think depending on which claims he finds are infringed, the basis for the infringement, the consequences could be different. I think it's hard to comment on that now. I mean, obviously, once we have the opinion, we'll have a more informed take on what we think the likely outcomes are. At this point, I think, as we've said consistently in our 10-Qs and other releases, we have a wide range of potential outcomes.

We're just waiting to see what the judge says.

Roger Jeffs (CEO)

Great. On the last question, obviously, we're not going to forecast patient numbers. I think what we have highlighted is that we've driven brand awareness very quickly. There's been significant uptake of YUTREPIA in this early launch phase, and our pull-through rate is very, very high at 85%. We don't see any further impediments to that. We're going to continue to try to position YUTREPIA as the best in class and first in choice process cycling and do what we need to do to benefit every patient that we can possibly benefit. With that, I think we'll end the call. I'd like to thank everyone for joining us today. We're really proud of the progress we've made in just a few short months and even more excited about what lies ahead. I hope everyone has a great day. Thank you.

Operator (participant)

Thank you for participating in today's conference. You may now disconnect.